



o aspect of the optimal management of
non-Hodgkin’s lymphoma patients is
more controversial than that of patients
with low-grade histologies. Standard regimens
including an alkylating agent proved to be pal-
liative treatments with a median survival of 5-8
years; aggressive regimens with anthracyclines
have not improved these results. High-dose
therapy followed by bone marrow or peripheral
blood stem cell support has also failed to pro-
long survival. 
Among conventional drugs, several trials
shown that idarubicin is effective, as single
agent, in the treatment of relapsed/refractory
non-Hodgkin’s lymphoma (NHL).1,2 In the last
few years two purine analogs, fludarabine (FLU)
and 2-chlorodeoxyadenosine (2-CdA), have
been used extensively in previously treated LG-
NHL patients,3-5 producing responses, mostly
partial, in 40-50% of patients. In particular, a
few investigators have reported data concerning
the efficacy and safety of the combination of flu-
darabine with mitoxantrone6,7 and fludarabine
with cyclophosphamide.8
On the basis of these data, we started a pilot
trial with FLU and idarubicin (FLU-ID regi-
men) in previously treated patients with LG-
NHL, and in this report we summarize our
experience.
Patients and Methods
From June 1994 to December 1994, 10
patients with LG-NHL were entered in this
phase II study. The main protocol requirement
was that patients initially had advanced (stage
III or IV) disease, as outlined by the Ann Arbor
Conference,9 for which first/second-line treat-
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ABSTRACT
Fludarabine (FLU) is a new antimetabolite chemotherapeutic agent with promising activity in
lymphoproliferative disorders and, in particular, in low-grade non-Hodgkin’s lymphoma (LG-
NHL). Recently, a few reports have described interesting results using FLU in polychemotherapy
regimens. In order to evaluate FLU in combination with other antineoplastic agents, we used a com-
bination of FLU and idarubicin, called the FLU-ID regimen, to treat 10 patients with recurrent LG-
NHL. The FLU-ID regimen was as follows: FLU 25 mg/sqm i.v. on days 1 to 3 and idarubicin 12
mg/sqm i.v. on day 1. Of the 10 patients, 2 (20%) achieved complete response (CR), 5 (50%) partial
response, and the remaining 3 showed no benefit from the treatment. The 2 CR patients are still in
remission after 6 and 8 months, respectively. The median duration of overall survival of all patients
was 8 months. The major toxic effects observed were neutropenia (40%) and infections and/or
febrile episodes (15%); no fatalities due to drug side effects occurred. These results indicate the effi-
cacy of the FLU-ID regimen in inducing a good remission rate with moderate side effects in recur-
rent LG-NHL.
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ment had failed to produce complete response
or relapse had occurred.
Criteria for entry into the study included: his-
tologic diagnosis of LG-NHL according to the
updated Kiel classification;10 the presence of
measurable disease; normal hepatic, renal, car-
diac function; radiation and chemotherapy had
to be discontinued at least 6 weeks before the
start of treatment. Informed consent was
obtained from all patients in accordance with
the ethical policy of the Institute.
The FLU-ID regimen schedule was as follows:
FLU 25 mg/sqm i.v. on days 1 to 3 and idaru-
bicin 12 mg/sqm i.v. on day 1. FLU was sup-
plied by Schering S.p.A. (Milan, Italy). Courses
were given at 3-week intervals for a maximum
of 6 cycles. All patients received bacterial and
Pneumocystis carinii prophylaxis with co-tri-
moxazole (2 days per week) only during the
entire course of therapy.
Patients were restaged after completion of 6
cycles. Clinical and pathologic evaluations were
made by repeating radiographic investigations
and bone marrow biopsy if previous results had
been positive.
Patient characteristics 
Of the 10 patients with LG-NHL, 6 were
males and 4 females and the mean age was 55
years (range 40 to 64 years). Six patients had
stage III and 4 stage IV disease; systemic symp-
toms were present in 3 patients. 
The time from the initial diagnosis of LG-
NHL to the start of the FLU-ID regimen ranged
from 12 to 25 months (median 18 months). All
these patients had previously received one (6
patients: 2 patients CHOP regimen, 2 CVP reg-
imen, and 2 patients VNCOP-B protocol), or
two (4 patients: 2 patients received CHOP and
CVP, and 2 CVP and VNCOP-B) chemotherapy
treatments. All the patients had recurrent,
relapsed disease and none presented resistant
disease; Table 1 depicts the pretreatment char-
acteristics of the 10 patients.
Response criteria
Complete response (CR) was defined as a
complete disappearance of signs and symptoms
due to lymphoma that was maintained for at
least 6 weeks; partial response (PR) was defined
as a reduction of at least 50% in the product of
two largest perpendicular diameters of all mea-
surable lesions for a duration of at least 6
weeks. Standard Eastern Cooperative Group
(ECOG) toxicity criteria were used.11
Results
Response
Of the 10 patients studied, 2 fulfilled the cri-
teria for CR and 5 for PR (70% overall response
rate); the remaining 3 patients did not respond
to the therapy. The likelihood of response cor-
related with the number of previous chemo-
therapy regimens. In fact, in the 6 patients who
had previously received only one regimen, 2 CR
and 2 PR were documented. In contrast, among
the 4 patients who had received two different
previous treatments, 3 PR were documented.
Concerning disease stage, we observed CR in
2 stage III patients; as for histology, the 2 CR
patients presented centroblastic/centrocytic fol-
licular lymphomas. Both complete responders
had obtained a first CR with the induction
treatment, and this remission had lasted for 9
and 11 months, respectively.
They are currently still in remission after 6
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Table 1. Characteristics of 10 LG-NHL patients treated with the FLU-ID
regimen.
N. of patients 10












Cb/Cc F= centroblastic/centrocytic follicular; Cb/c F & D= centroblastic/centrocytic
follicular and diffuse; Ic= immunocytoma lymphoplasmacytoid.
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and 8 months, respectively. None of the other
responses have been maintained. Among the
partial responders, one progression was
observed and this patient died from the disease.
The median duration of overall survival of all
patients was 8 months (range 6 to 16 months).
Toxic effects
The FLU-ID regimen was well tolerated in
general, and all patients completed the therapy.
With regard to hematologic toxicity, neutrope-
nia was observed in 4 (40%) patients, 1 of
whom reached grade 3 or 4 (neutrophil count
less than 13 109/L), whereas thrombocytopenia,
which was observed in 3 patients, was much less
severe (grades 1 and 2)(platelet count between
50 and 1003109/L). Five (8%) of a total of 60
courses were temporarily postponed for one
week because of neutropenia and/or thrombo-
cytopenia, but no trend toward cumulative
myelosuppression was observed.
Other major toxic effects were represented by
infections; 1 episode of pneumonia and one
moderately severe febrile episode in a neu-
tropenic patient who showed negative cultures.
No direct correlation was noted between the
intensity of neutropenia after treatment and the
incidence of febrile episodes. Cardiac, liver and
renal side effects were not observed, and no
fatalities due to drug side effects occurred.
Discussion
In this study, the 10 recurrent LG-NHL
patients evaluated for response and toxicity to
the FLU-ID regimen registered an overall
response rate of 70%, with a CR rate of 20%. 
LG-NHL continue to represent a challenge
for hematologists. Patients with LG-NHL
respond well and often achieve CR with con-
ventional alkylating agent-based chemotherapy,
but early relapses are frequent; only approxi-
mately 25% of patients are free of disease at 5
years. There is no standard therapy for patients
who relapse after or become refractory to alky-
lating agents. Treatment options range from a
watch and wait approach for asymptomatic
patients to intensive high-dose chemo-radio-
therapy with bone marrow or stem cell trans-
plantation.12
Recently, FLU and 2-CdA, either alone3-5 or in
combination with other drugs,6-8,13 have shown
promising therapeutic activity of previously
treated and untreated patients with LG-NHL. 
Our results with the FLU-ID regimen are
encouraging and confirm those observed with
fludarabine and mitoxantrone;6,7 in fact, we
observed a higher overall response rate as well
as a greater percentage of complete responders
than that obtained with FLU alone.3-5 The toxic
effects of this regimen were acceptable, with
neutropenia and infections being the most
prevalent problem.
The above studies on FLU alone indicate that
this drug effectively induces remission in
patients with LG-NHL, particularly those with
follicular histology. However, as with other
therapeutic modalities for LG-NHL, remission
is rarely maintained beyond two years.14 On the
basis of these data, a fludarabine-idarubicin
combination-containing regimen is associated
with a significantly higher overall response rate
and complete response rate respect to with FLU
alone in relapsed and advanced LG-NHL
patients. Therefore these data indicate that
FLU-ID-based regimens should be incorporat-
ed into first-line randomized trials of LG-NHL
that compare fludarabine-containing schemes
and other LG-NHL treatments, in order to
evaluate possible advantages with regard to
remission induction and duration of response.
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